cyrilzakka/clinical-trials huggingface dataset:
Comparison of Posterior-anterior Spinal Mobilization and Prone Press up in Patients With Non Specific Low Back Pain

No previous literature found on the comparison of posterior-anterior spinal mobilization and prone press-up on pain, range of motion and disability in patients with non-specific low back pain. This study will approach the results of posterior- anterior spinal mobilization and prone press-up on pain, range of motion and disability in patients with non-specific low back pain. In previous researches the patients were not properly followed to see pre session, immediate after the session and after twenty- four hours effects of both interventions Posterior- anterior mobilization and Press-ups. Secondly, they have not taken the control group in their studies. In current study two techniques along with conventional treatment will be compared in three different groups to see their individual effects and combine effect of Maitland and Mackenzie technique

Non-specific low back pain refers to pain without any specific cause. The term "non- specific low back pain" refers to a condition where the cause of the symptoms cannot be identified with certainty, indicating that the underlying pathology is currently unknown and difficult to diagnose reliably. This pain is known for the main leading cause to effect activities of daily life, absenteeism and health care. Non-specific low back pain is a widely known serious condition in the worldwide . this was a randomized control trial and patients were randomly selected according to inclusion criteria and divided into A and B and C groups. The base line demographic, clinical and disability data was collected through structured questionnaire. Group A received both posterior-anterior mobilization on L4 and L5 level and Prone press- ups technique along with a conventional therapy whether group B had received only posterior-anterior spinal mobilization along with the conventional therapy. While group C received prone press-ups technique along with conventional treatment. Patient outcomes were measured at baseline, immediate after the session and 24 hours after the session outcomes measures (NPRS, GONIOMETER, ODI).

Eligibility Criteria:
Inclusion Criteria:

* Non-specific low back pain of duration \<3 months
* Both male and female Age 22-40
* Increased localized pain with lumber extension during standing
* NPRS \< 6

Exclusion Criteria:

* Spinal Surgery
* Subject who administered epidural injections
* Psychological low back pain
* History of injury from past 3 months
* Neurological deficit
* Hyper-mobility
* Subjects with mental disorder
Pharmacokinetics and Point of Care Testing of Direct Oral Anticoagulants Subjects

DOACs are increasingly used since 8 years. Standard coagulation tests (Prothrombin time \[PT\] and activated partial thromboplastin time \[aPTT\]) from plasma samples show a high variation. Special coagulation tests like hemoclot for dabigatran and chromogenic substrate assays for Rivaroxaban, Apixaban, and Edoxaban are time-consuming and can be performed only in specialized laboratories. In specific medical situations like in patients such as emergency procedures, stroke (before starting thrombolytic therapy), trauma, general surgery or other invasive procedures, it may be necessary for medical decision making to know the presence or absence of a DOAC in patient's body fluid. Until now there is no rapid, specific and sensitive coagulation test available in the market.

This prospective, open-label, controlled, not randomized trial in healthy volunteers to investigate comparatively the pharmacokinetics of the direct oral anticoagulants in plasma and in urine with LC-MS/MS and in urine by DOAC Dipstick.

Eligibility Criteria:
Inclusion Criteria:

* Fully signed and dated written informed consent

  * Age \>18 years
  * healthy

Exclusion Criteria:

* Patients not able to provide urine samples.

  * Patients not able to understand the informed consent or severe mentally disabled.
  * Patients in the end-stage of a severe disease.
Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST)

Physicians tend to always use the lowest dose of statins to initiate therapy even in subjects who require large reductions in cholesterol. The study evaluates if selecting the starting dose based on baseline and target LDL-C cholesterol would provide better results (ie proportion of subjects resching target)


Eligibility Criteria:
Inclusion Criteria:

* High cholesterol blood levels (LDL-cholesterol above 100 mg/dL up to 220 mg/dL.
* Triglycerides up to 600 mg/dL.
* History of coronary artery disease (ex.: heart attack, angina), stroke, diabetes or at high risk of such events

Exclusion Criteria:

* Pregnancy or lactation, use of high statin doses (\>40mg) at baseline, liver or renal problems, use of other drugs that would interfere with evaluation of efficacy or cause safety problems, uncontrolled hypertension, diabetes or hypothyroidism, recent cardiac event of procedure, high baseline CPK levels
Fibrates in Pediatric Cholestasis

A study conducted to assess the effect of fibrates on pruritus and biochemical picture in pediatric patients with cholestatic liver diseases.

Cholestatic liver disorders include a spectrum of hepatobiliary diseases of diverse etiologies that are characterized by impaired hepatocellular secretion of bile, resulting in accumulation of bile acids, bilirubin and cholesterol.This could result in different clinical features including pruritus, malabsorption and vitamin deficiencies with subsequent coagulation disorders and bone disease. Persistence of cholestasis leads to biliary fibrosis which can progress to liver cirrhosis and end-stage liver disease.

Nuclear receptors (NRs) regulate ligand-activated transcription factor networks of genes for the elimination and detoxification of potentially toxic biliary constituents accumulating in cholestasis. Activation of several NRs also modulates fibrogenesis, inflammation, and carcinogenesis as sequelae of cholestasis. Hence, It represent attractive targets for pharmacotherapy of cholestatic disorders.

Several already available drugs may exert their beneficial effects in cholestasis via NR activation eg, ursodeoxycholic acid via glucocorticoid receptor and pregnane X receptor, and rifampicin via pregnane X receptor. Unfortunately, Some patients may not respond to these medications.

Fibrates, serum Lipid lowering medication, has a stimulation action on proliferator activated receptor alpha. It is a nuclear receptor with an integral role in bile homeostasis. Several case reports and pilot studies have demonstrated the efficacy of fibrates in reducing serum biomarkers of cholestasis and liver function abnormalities in patients with incomplete response to ursodeoxycholic acid monotherapy. These results are of interest, because fibrates are attracting increased attention as adjunct therapy for chronic cholestatic liver diseases.

Eligibility Criteria:
Inclusion Criteria:

* Patient with chronic cholestatic liver disease defined as any condition in which substances normally excreted into bile are retained for more than 6 months.

Exclusion Criteria:

* Patients with anatomical or mechanical obstructive causes for cholestasis.
* Cholestatic patients who were suffering from another liver disease.
* Cholestatic patients who were receiving drugs affecting lipid profile.
* Patients receiving drugs that interact with Fenofibrate (FF) e.g statins and warfarin
* Patients with non obstructive gall bladder stones were excluded from T gp.
A Multiple-Dose Study of RhuMab 2C4 and Docetaxel in the Treatment of Advanced Solid Tumors

This study will evaluate the safety, tolerability, and pharmacokinetics of the combination of rhuMab 2C4 (Perjeta) and docetaxel (Taxotere) in participants with advanced solid tumors that have progressed during or after standard therapy, or for which no standard therapy is available. Participants will be enrolled and evaluated for dose-limiting toxicities (DLTs) in escalating-dose cohorts in order to determine the maximum tolerated dose (MTD).


Eligibility Criteria:
Inclusion Criteria:

* Adults at least 18 years of age
* Easter Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Life expectancy at least 12 weeks
* Locally advanced or metastatic solid tumor with at least 1 measurable lesion, which has progressed during/after standard therapy
* Human epidermal growth factor receptor 2 (HER2)-negative among participants with breast cancer
* Negative pregnancy test or use of an adequate contraceptive method among women of childbearing potential
* Adequate hematologic, hepatic, and renal function
* Signed informed consent, histologically or cytologicall confirmed advanced solid tumor, adequate cardiac function as documented by LVEF \>50% by ECHO or MUGA

Exclusion Criteria:

* Clinical evidence of central nervous system (CNS) metastases
* Prior chemotherapy, radiotherapy, or immunotherapy within 4 weeks, or hormone therapy within 2 weeks of study Day 1
* History of neuropathy Grade 2 or worse, or any unresolved residual chemotherapy effects
* Prior HER2-active agents or docetaxel
* Any investigational agent within 28 days of study drug
* Prior cumulative doxorubicin dose greater than (\>) 360 mg/m\^2 or equivalent
* Significant cardiovascular disease
* Active/uncontrolled concurrent illness or infection-
* Major surgery or trauma within 4 weeks of study Day 1
Simulator of Pompage Technique for Physiotherapists

Parameterize the Pompage technique with an anatomical model cervical region to simulate specific procedures. Quantify the times, displacements, and facilitate the training of students and professional of physical therapy.

Manual techniques are taught and trained with practical demonstration without technology support to measure them, so they are difficult to reproduce. This difficulty increases in Pompage technique because the student is not able to estimate the displacement on the skin. In this research, to parameterize and train the technique was developed and validated an anatomical model of the cervical region, with silicone and latex rubber. The anatomical model simulates the soft tissues and a plastic resin structure represents the cervical spine bone. An optical sensor was used to measure the displacements performed on simulated skin versus time. The Likert scale was used for assessing the similarity of the anatomical model relative to the size, shape, texture, elasticity and displacement of the skin as well as the curvature of the cervical spine. Five experienced professionals (GP) in the technical performed five series of Pompage technique. With the mean of data collected were determined benchmarks for technical and implemented in a standard guide to train the volunteers. Twenty-six volunteers (GE) with no experience performed the Pompage technique, with the anatomical model following the standard guide. A physical therapist (VE) was selected to evaluate the volunteers (GE) before and after training in the simulator.

Eligibility Criteria:
Inclusion Criteria:

* no history of cervical trauma (GT and VF)
* Do not have dermatitis in the cervical region (GT and VF)
* recurrent migraines (GT and VF)
* no prior knowledge of Pompage technique (GE).
* minimum 5 years experience of applying the Pompage technique (GP and VE).

Exclusion Criteria:

* report pain in the cervical region (GT and VF)
* irritations in the cervical region (GT and VF)
Efficacy of Thrombosuction in Primary Percutaneous Coronary Intervention of Acute Myocardial Infarction

The present study was designed to investigate whether the thrombus aspiration using Export Aspiration Catheter (Medtronic Corporation, California, USA) during primary percutaneous coronary intervention (PCI) in acute myocardial infarction improve clinical outcomes.

Primary percutaneous coronary intervention (PCI) is the preferred strategy for immediate revascularization in patients with acute ST-elevation myocardial infarction (STEMI). A meta-analysis of trials comparing primary PCI to fibrinolytic therapy showed a mortality benefit to the invasive approach. However, although TIMI III flow is achieved in the culprit epicardial vessel in the majority of patients, lack of tissue-level reperfusion is observed in approximately 30% of patients as manifested by persistence of chest pain and ST-segment elevation. Many strategies have tried to overcome this problem, from mechanical thrombectomy and distal protection devices to myocardial preserving agents. The purpose of present study is to investigate the efficacy of the thrombus aspiration using Export Aspiration Catheter (Medtronic Corporation, California, USA) during primary PCI in acute myocardial infarction.

Eligibility Criteria:
Inclusion Criteria:

* Patients with first ST-elevation myocardial infarction who undergo primary PCI within 12 hours after symptom onset
* Patients who are eligible for PCI

Exclusion criteria

* History of bleeding diathesis or coagulopathy
* Pregnant
* Known hypersensitivity or contra-indication to contrast agent
* Left main disease
* In-stent restenosis lesion
* Graft vessels lesion
* Chronic total occlusion lesion
* Renal dysfunction, creatinine more than 2.0 mg/dL
* Contraindication to aspirin, clopidogrel or cilostazol
* Prior PCI or bypass surgery
* Old myocardial infarction
The Effect of Education and Counseling Based on HypnoBreastfeeding

The aim of this study is to determine the effect of education and counseling based on the hypno-breastfeeding philosophy given in the antenatal period on only breastfeeding status, breastfeeding self-efficacy and breastfeeding motivation.

This is a non-randomized experimental study. Data were collected from 80 women who attended hypno-breastfeeding-based education or standart breastfeeding education from Turkey between September 2021 and February 2022. Participants who met the inclusion criteria were informed about the purpose of the study and hypno-breastfeeding-based education or standart breastfeeding education, informed consent was obtained from those who agreed to participate. Data were collected at the time of consent to the study, pre-education, post-education, 1 week and 8 weeks after birth. Collected by the first author. The CONSORT directive was followed in the planning, implementation and writing of the research.

Eligibility Criteria:
Inclusion Criteria:

* Must be able to a healthy pregnancy,
* Native language is Turkish,
* Have single fetus
* Must be able to breastfeeding with her baby
* Must be able to join wit education.

Exclusion Criteria:

* Complications,
* Psychological or psychiatric disorder,
* Un-available follow-upps
Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation

The purpose of this study is to determine if the incidence of Graft vs. Host Disease (GVHD) after non-myeloablative transplantation can be reduced by using a combination of three immune suppressive medication; sirolimus, tacrolimus and methotrexate.

* Patients will be admitted to the hospital and receive chemotherapy and stem cell transplant(SCT). The total duration of hospitalization for the procedure is approximately 8 days. Once admitted the patient will receive fludarabine daily for 4 days, busulfex once daily for 4 days. Two days after chemotherapy has ended, the patient will receive the infusion of donor cells.
* Just prior to the transplant and following the transplant, patients will receive sirolimus (orally), tacrolimus (orally) and low doses of methotrexate (chemotherapy). Methotrexate will be given on days 1,3 and 6 after transplant.
* Sirolimus will be tapered beginning week 9 after transplant if there is no evidence of GVHD and will be eliminated on week 26 if clinically feasible.
* Tacrolimus will be tapered beginning week 9 after transplant if there is no evidence of GVHD and will be eliminated on week 26 if clinically feasible.
* Patients will also receive medication to help prevent possible infection.
* After stem cell infusion, patients will be examined and have blood tests weekly for 1 month. At the 1 month visit, a bone marrow biopsy will performed looking for evidence of donor cells in the bone marrow. After the one month evaluation the patient will be examined every 2 weeks and a repeat bone marrow performed 3-4 months after transplant.

Eligibility Criteria:
Inclusion Criteria:

* Patients with hematologic malignancies who are at a high risk of complications after conventional transplantation.
* Donors (both related and unrelated) who are identical at 6 HLA loci.
* Age greater than 18
* ECOG Performance Status 0-2
* Life expectancy of greater than 100 days.

Exclusion Criteria:

* Pregnancy
* Evidence of HIV infection
* Heart failure uncontrolled by medications
* Total Bilirubin \> 2.0mg/dl due to hepatocellular dysfunction
* AST \> 90
* Serum creatinine \> 2.0
* Cholesterol \> 300 mg/dl
Early Bandage Removal Post-Cesarean Delivery

Women undergoing their first second or third cesarean section will be randomized into two groups. One group will have the abdominal bandage removed at 6 hours post-surgery and the other group will have the bandage removed at 24 hours. Staple removal will be at 5 - 7 days for both groups. The incision will be inspected at the time of staple removal. The 2 groups will be compared for incision disruption and infection. Also, the women will be asked about their satisfaction for time of bandage removal.


Eligibility Criteria:
Inclusion Criteria:

* age of 18 to 44
* elective cesarean section, primary or repeat
* low risk pregnancy

Exclusion Criteria:

* under the age of 18 and above the age of 44
* diabetes, preeclampsia or other pregnancy complications
* unable or unwilling to give informed consent
* chorioamnionitis
* BMI over 35
* more than 3 cesareans
Screening for Postoperative Vital Signs Abnormalities, and Particularly Hemodynamic Ones, by Continuous Monitoring Using the Biobeat Patch

Brief Summary: Post-operative morbidity remains a reality as shown by the International Surgical Outcomes Study published in 2016 and 2019 and by several recent publications which focus mainly on hypotension and cardio-vascular complications. Other complications, such as respiratory depression, are less often studied. The hypothesis is that this connected patch could be used in surgical departments to detect a postoperative complication.

Biobeat Technologies Ltd has developed a sensor which continuously records the photoplethysmographic waveform and allows the calculation of several physiological parameters: heart rate (HR), oxygen saturation (SpO2), systolic blood pressure (SBP), diastolic blood pressure (DBP), stroke volume (SV), cardiac output (CO), cardiac index (CI), systemic vascular resistance (SVR), respiratory rate (RR), and temperature.

The objective of this study is the quantification of hemodynamic, respiratory and temperature abnormalities detected by routine monitoring (routine nursing follow-up) and continuous monitoring by the Biobeat patch during the first 72 postoperative hours.


Eligibility Criteria:
Inclusion Criteria:

* Patient 18 years of age or older
* Patient undergoing major digestive, gynecological, orthopedic or urological surgery (expected duration of surgery greater than 2 hours).
* Predictable postoperative hospitalization duration ≥ 2 nights
* Patient with a Health Insurance plan
* Not having opposed participation in the research

Exclusion Criteria:

* Patient with significant deformity, swelling, irritation or with localized infection, ulceration or skin lesions on the torso
* Patient with a subcutaneous electronic pacemaker implant.
* Patient with a CT or MRI scan already scheduled for the first three days postoperatively
* Patient suffering from tremors or convulsions
* Patient with a torso tattoo
* Patient with significant chest hairiness
* Patient with a known allergy to metals, plastics and silicone
* Patient deprived of liberty or under guardianship
* Pregnancy or breastfeeding
Illness Crisis Adapting in Early or Middle Phase of Patient With Chronic Disease: Study of Meta-cognition Model

Patient with chronic disease learning of a chronic illness quickly changes the way they encounter in physiological, psychological and social aspects. The investigators research purposes will use the meta-cognitive approach to explore adjustment to life-threatening illness (ex. hypertension and diabetes) of patients may find the important factors in their coping process.

Patient with chronic disease learning of a chronic illness quickly changes the way they encounter in physiological, psychological and social aspects. They need adjust themselves and their crisis lives, and some plan they had made the near or distant future. The investigators research purposes will use the meta-cognitive approach to explore adjustment to life-threatening illness (ex. hypertension and diabetes) of patients may find the important factors in their coping process.Research methods will separate three year project to describe. First year project will use qualitative methods from bio-psychosocial aspects to interview participants who may suffer illness after diagnosis or stable treatment during middle phase of illness. Second year will invite diabetes and hypertension patients from different phase of illness with different levels of health anxiety trait, meta-cognitive and control strategies if derived different coping and emotions outcome. The third year will design motivational psycho-education program for patients to alleviate the emotions and use cold meta-cognition to due good health behavior and self care with their illness. The expected results will like to test the investigators new model in caring chronic disease patients.

Eligibility Criteria:
Inclusion Criteria:

* adults aged 20 and above, with hypertension or diabetes or both diseases.

Exclusion Criteria:

* adults with other severe physical diseases.
* adults with relevant psychological diseases.
Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis

-Rivaroxaban is factor Xa inhibitor

PVT is a common complication of liver cirrhosis

Eligibility Criteria:
Inclusion Criteria:

* Acute PVT

Exclusion Criteria:

* Malignant PVT
* Bleeding disorders
ENOSE in Pulmonary Tuberculosis in Yogyakarta

Electronic noses detecting patterns of volatile molecules have recently been introduced for different diagnostic purposes. The diagnostic accuracy of a prototype e-nose device (Bruins et al (2013) in Bangladesh showed sensitivity of 76.5-95.9% and specificity of 85.3-98.5%. Here the investigators test a production type point-of-care hand-held device with less detectors. The investigators explore factors such as food intake, smoking, and co-morbidity, as well as the impact of TB treatment, and address the question whether the device could help monitor disease and response to treatment.

Study participants provide WIC and after time for consideration, when they approve, provide demographic anonymized data.

The study population consists of six groups:

Group 1 - 20 TB patients aged \> 18 yrs Group 2 - 20 non---TB patients \> 18 yrs (screened for TB - other conditions) Group 3 - 20 patients with a lung disease - no TB suspects (Lung Clinics in Yogyakarta,Indonesia; Group 4 - 50 apparently healthy matched controls Group 5 - 20 newly diagnosed TB patients enrolled before start of treatment, to be followed over time, until after end of treatment (8 months FU).

Group 6 - 50 apparently healthy volunteers.

Study participants breath normally by mouthpiece into the device using a nose clamp - for 5 min during each sampling.

Electronic data are downloaded and transmitted by internet to Zutphen, Netherlands where data are processed to build the model.

Eligibility Criteria:
Inclusion Criteria:

* age \>18yrs
* voluntarily participating

Exclusion Criteria:

-